肝癌免疫治疗靶点
本文综述肝细胞癌(HCC)免疫治疗的理论依据、作用机制及免疫检查点阻断的临床数据,并概述过继性细胞治疗和抗体类等新型免疫治疗方法的开发现状。HCC作为炎症诱导的癌症是免疫治疗的理想靶点,早期临床试验结果良好并已进入III期评估。
要点
- HCC是炎症诱导的癌症,为免疫治疗提供了理想靶点。
- 免疫检查点抑制剂早期临床试验结果良好,已进入III期评估。
- 过继性细胞治疗和抗体类方法等新型免疫治疗正在开发中。
核心结论
- 免疫检查点阻断在HCC中具有理论依据和早期临床前景,已进入III期评估。
- 其他新型免疫治疗方法如过继性细胞治疗和抗体类方法正在开发中。
研究设计与样本
- 本文为综述,总结HCC免疫检查点阻断的理论依据、作用机制和临床数据,并概述其他新型免疫治疗方法。
主要发现
- HCC作为炎症诱导的癌症是免疫治疗的有趣靶点。
- 免疫检查点抑制剂早期临床试验结果不仅良好,且已推动III期评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug development in hepatocellular carcinoma (HCC) has been characterised by many failures in the past. Despite good rationales and promising phase II data, many phase III trials failed. Immunotherapy represents an alternative treatment approach that has been successful in many different cancer types. As an inflammation induced cancer, HCC represents a very interesting target for immune based approaches. Indeed, early results from clinical trials testing immune checkpoint inhibitors are not only promising, but have already led to evaluation in a phase III setting. Herein, we summarise our current knowledge on the rationale, mechanism of action and clinical data for immune checkpoint blockade in HCC. In addition, we provide an overview of other novel immune based approaches currently under development for the treatment of HCC, such as adoptive cell based and antibody-based approaches.
引用
- Greten TF, Sangro B. Targets for immunotherapy of liver cancer. J Hepatol. 2017. PMID: 28923358. doi:10.1016/j.jhep.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。